

Popular diets and nutritional assessment in the management of irritable bowel syndrome in inflammatory bowel disease: an overview of current evidence

Carlo Covello^{1,2}, Guia Becherucci³, Franco Scaldaferri^{1,4}, Lucrezia Laterza¹, Antonio Gasbarrini^{1,4}, Maria C. Mentella³

¹ IBD Unit, Centro di Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

² Gastroenterology Department, CEMAD, Center for Diagnosis and Treatment of Digestive Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

³ UOC di Nutrizione Clinica, Dipartimento Scienze Mediche e Chirurgiche Addominali ed Endocrino-Metaboliche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

⁴ Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy

KEY WORDS

diets, inflammatory bowel diseases, irritable bowel syndrome, malnutrition, sarcopenia

ABSTRACT

There is an increasing interest in using popular diets to manage inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn disease. These conditions are often associated with nutritional deficiencies, protein-energy malnutrition, micronutrient malnutrition, altered body composition, and sarcopenia. While dietary interventions can be supportive in treating intestinal symptoms of adult IBD patients, it is important to note that current guidelines from major scientific societies do not recommend any specific dietary interventions in this field. This review aims to provide a summary of the current evidence on dietary-nutritional management for patients with IBD, specifically when the disease appears to be in remission, but the patient continues to experience irritable bowel syndrome (IBS) symptoms or functional gastrointestinal symptoms. We focus on vital aspects, such as malnutrition and sarcopenia definitions, screening, and nutritional assessment. We then discuss in detail the most popular diets used for IBD management over the years, characterizing each one in terms of effects on gut inflammation, IBS-like symptoms, and potential risk of malnutrition. These diets include a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet, a gluten-free diet, a Mediterranean diet, and a plant-based diet. To date, current evidence does not conclusively establish the optimal diet for patients with IBS, suggesting that personalized dietary approaches may be the best strategy.

Correspondence to:
Carlo Covello, MD,
Gastroenterology Department,
Centro di Malattie dell'Apparato
Digerente (CEMAD), Fondazione
Policlinico Universitario A. Gemelli
IRCCS, Largo Gemelli 8, 00168 Rome,
Italy, phone: +39 333 1534655,
email: covellocarlo@gmail.com
Received: November 26, 2023.
Revision accepted: January 2, 2024.
Published online: January 9, 2024.
Pol Arch Intern Med. 2024;
134 (2): 16659
doi:10.20452/pamw.16659
Copyright by the Author(s), 2024

Introduction Inflammatory bowel diseases (IBDs), such as Crohn disease (CD) and ulcerative colitis (UC), are inflammatory conditions affecting the gastrointestinal system. The exact causes of these diseases are not fully understood, but research suggests that they result from an abnormal immune response to gut microbes in genetically susceptible individuals, possibly triggered by environmental factors.¹ CD can affect any segment of the gastrointestinal tract with transmural involvement, whereas UC typically involves the mucosa and submucosa of the colon tract.²

Over the last few decades, the prevalence of IBD has been increasing in many regions around the world. In Poland, nationwide data from 2009 to 2020 confirm a significant rise in the disease burden.³

These conditions have been demonstrated to be associated with nutritional deficiencies and metabolic changes, mainly due to chronic inflammation. Malabsorption with increased intestinal protein loss and decreased dietary intake represent the main factors related to malnutrition in IBD patients.⁴

Malnutrition is a serious condition that can have adverse clinical outcomes.⁵ The World Health

Organization defines malnutrition as a deficiency, excess, or imbalance in the intake of energy and/or nutrients, leading to altered body composition and cell mass.⁶ Malnutrition can cause sarcopenia, which is a condition characterized by a decrease in skeletal muscle mass, strength, and function. Sarcopenia is associated with an increased risk of mortality and diminished well-being.⁷ Malnutrition can express itself as caloric-protein and micronutrient malnutrition, and is associated with very poor quality of life, low response to therapy, and, therefore, clinical outcomes in IBD patients.⁸

It is important to note that some patients in remission may still experience gastrointestinal symptoms that are often attributed to irritable bowel syndrome (IBS) by their health care provider. According to a recent meta-analysis, this condition affects almost 40% of the IBD patients, which is significantly more than in healthy individuals, even when the patients are in remission.⁹ Managing the symptoms and related malnutrition can be challenging, but understanding dietary habits of the patients can make a significant difference. By implementing a tailored dietary regimen, the patients can better manage their symptoms and improve their health. Therefore, it is crucial to consider specific dietary needs of each patient in order to provide them with comprehensive care.¹⁰ Studies show that eating well is important for IBD patients. As many as 90.4% of them believe that a balanced diet is essential to control IBD, and 86.2% think that a more individualized diet could reduce their symptoms.¹¹ Another study shows that 86% of IBD patients strictly follow diets also in remission phase, which leads to malnutrition and micronutrient deficiency.¹²

The purpose of this review is to provide an overview of the dietary and nutritional management of IBD patients who appear to be in remission but continue to experience IBS-like or functional gastrointestinal symptoms. We will discuss important topics, such as definitions of malnutrition and sarcopenia, nutritional screening and assessment, and popular diets that have been attempted for IBD over the years. We will also characterize each diet, analyze their effects on gut inflammation and IBS-like symptoms, and determine which diets pose a risk in terms of malnutrition.

Determinants of malnutrition and characterization of sarcopenia in inflammatory bowel disease Malnutrition in IBD is characterized by protein-energy malnutrition (PEM), altered body composition, and micronutrient deficiency, and it can be determined by multiple factors⁸ influenced by the nature and severity of the disease.

A decrease in oral food intake is one of the most important reasons for malnutrition in patients with IBD.¹³ When there is chronic inflammation, proinflammatory cytokines are produced and that can result in anorexia.⁴ Proinflammatory cytokines are also linked to an increase in

the prevalence of chronic fatigue and breakdown of muscle proteins, causing muscle atrophy.¹⁴ Moreover, circulating appetite regulators, such as gastric mediators (leptin and ghrelin) may regulate the anorexic process. Additionally, other symptoms and comorbidities, such as interleukin (IL)-6-induced depression,¹⁵ may result in decreased nutrient intake, elevated resting energy expenditure, suppression of anabolic hormones (such as growth hormone, insulin-like growth factor 1, and testosterone), or even hormonal factor resistance.¹⁶ This condition involves a reduction in appetite and therefore poor oral intake of nutrients.¹³ Nausea, vomiting, abdominal pain, and diarrhea contribute to the loss of appetite.⁸

Malabsorption is the second determinant of malnutrition. It is especially common in patients with CD and small intestine involvement, as well as in those with UC. The same proinflammatory cytokines mentioned earlier, which are released by immune cells in the intestinal mucosa during active and remission phases, cause changes in the epithelium, such as altered ion transport and a loss of epithelial integrity. This results in electrolyte, water, and protein loss leading to nutrient malabsorption and, in the active phase of the disease, inflammatory diarrhea.¹⁷ Additional causes of malabsorption include consequences of surgeries such as ileal, ileocecal, and colic resection. Bile acid malabsorption following ileal resection can lead to bile salt diarrhea.¹⁸ Other conditions causing malabsorption include infections, for example, with *Clostridioides difficile* and bacterial overgrowth conditions.¹⁹

Other determinants of malnutrition include high energy expenditure in IBD patients with body weight below 90% of ideal body weight or prolonged use of drugs such as glucocorticoids, which can interfere with absorption and utilization of calcium, phosphorus, and zinc, and are associated with bone changes and osteoporosis.¹⁶

Sarcopenia can be defined as a muscle disease characterized by adverse muscle changes that accumulate over time. A diagnosis of sarcopenia is based on low levels of muscle strength and muscle quantity/quality.²⁰

Thus, when malnutrition progresses into a generalized loss of muscle mass and function, a condition of sarcopenia is likely to develop. However, in IBD patients, sarcopenia may be also caused by some other etiopathogenetic mechanisms that are described below.

Up to 50% of IBD patients suffer from sarcopenia,²¹ resulting in a decrease in muscle mass of up to 60%, as compared with healthy individuals.²² Sarcopenia correlates with increased frequency of hospitalization, surgery, postoperative complications, and IBD severity, predicting adverse outcomes.²³

There are several mechanisms of sarcopenia development, one of which is due to prolonged PEM leading to a gradual decline in muscle mass. In individuals with IBD, the incidence of PEM ranges from 36.7% to 65%, and its severity and type

depend on the geographic extent, activity, and duration of the disease.²² Micronutrient malnutrition can also contribute to the development of sarcopenia, as in the case of vitamin D deficiency discussed in further sections of this review.

The muscle-gut axis is another mechanism that contributes to the development of sarcopenia. Gut microbiota plays a crucial role in controlling lean mass and can cause low-grade inflammation, which alters the immune response and host metabolism. This, in turn, upregulates several molecular pathways that are related to sarcopenia.^{24,25} Expression of mitochondrial proteins that are involved in energy production and control of the inflammatory cascade activation is positively associated with short-chain fatty acids (SCFAs) produced by gut bacteria. IBD patients often have lower levels of bacteria that ferment fibers and generate SCFAs, which can lead to lower SCFA production and chronic subclinical inflammation. This inflammation can then strengthen the anabolic resistance of skeletal muscles.²²

Sarcopenia also correlates with a degree of systemic inflammation and serum levels of tumor necrosis factor α (TNF- α). TNF- α stimulates synthesis of proteases, which can cause apoptosis of intestinal epithelial cells and increase degradation of muscle proteins.²⁶

Nutritional screening and assessment Nutritional screening and nutritional assessment are 2 components of malnutrition and sarcopenia examination in IBD patients.²⁷

Nutritional screening, using questionnaires and clinical history, is useful to evaluate the risk of malnutrition. The initial evaluation should include an analysis of symptoms (weight loss, anorexia, nausea, vomiting), IBD-related complications, such as strictures and fistulas, and micro- and macronutrient deficiency.²⁷ When used correctly and consistently, the nutritional screening tool identifies individuals at a risk of malnutrition. An ideal nutritional screening tool considers severity of the condition and adds dynamic indicators, such as recent weight loss, body mass index (BMI), and food intake. There are currently different questionnaires in use. The NRS-2002 is one of the nutritional risk screening tools that is most frequently used in hospitals around the world. The NRS-2002 is a validated instrument to perform prescreening in the form of 4 questions.²⁸ This screening evaluates nutritional status, static and dynamic parameters, disease severity, and other factors. Each parameter can receive a score between 0 and 3. In patients whose overall score is 3 or more, nutritional therapy is necessary, as they are either malnourished or at a risk of malnutrition. Additionally, Saskatchewan IBD-Nutrition Risk (SaskIBD-NR) and modified Malnutrition Universal Screening Tool (mMUST) have been developed and validated in IBD outpatients.²⁹

Patient and dietary history, anthropometric measures, and biochemical information are all

included in the nutritional assessment. The main aim of the nutritional assessment is to determine the severity of malnutrition and to develop an appropriate treatment.³⁰ In nutritional assessment, the results of functional measures are important. Therefore, knowledge of muscular strength and function is essential in the clinical setting. The handgrip test, which measures patient's strength, has been validated as a nutritional marker. It is a reliable indicator of both short- and long-term mortality and a quick and simple test which accurately recognizes the intensity of patient's strength in real time.³⁰ It is also important to know the patient's prescribed medications and to analyze their possible interactions with appetite, gastrointestinal function, or gastrointestinal symptoms. An analysis of dietary habits, including calorie and nutrient intake, consumption of certain foods or nutrients, frequency and composition of meals, and eating environment, is also essential.¹¹

Anthropometric measurements and body analysis can provide important information about the nutritional status of a patient. Body weight and height are essential anthropometric measures used for calculating BMI. BMI below 18.5 kg/m² indicates underweight, between 18.5 and 24.9 kg/m² indicates normal weight, between 25 and 39.9 kg/m² overweight, and above 30 kg/m² obesity.³¹

When a patient is suspected of malnutrition or sarcopenia, it is crucial to conduct a body composition analysis. **TABLE 1** summarizes the main techniques used for such an analysis. Using these instruments along with strength assessment methods can help identify sarcopenia in clinical practice.

Magnetic resonance imaging (MRI) and computed tomography (CT) are considered the gold standards for noninvasive assessment of body composition and muscle quantity/mass.³² However, these tools are not commonly used in health care due to high equipment costs and lack of portability.

Bioelectrical impedance analysis is a noninvasive technique that indirectly measures the body ability to a flow of current or impedance. It calculates the amount of water present in the tissues and indirectly measures the lean mass of the body. Parameters such as reactance, resistance, and phase angle are combined with anthropometric variables (weight and height), sex, and age³³ in order to analyze total body water, extracellular water, intracellular water, lean body mass, skeletal muscle mass, body cell mass, and fat free mass.

Dual energy X-ray absorptiometry is considered an excellent method for body composition analysis, and it is increasingly often used in clinical practice despite a risk of radiation exposure.²⁷ It can discern variations in density of bone mineral content, lean body mass, and fat mass. Adult osteopenia and osteoporosis are not diagnosed using whole-body densitometry bone mineral density data.³⁴

TABLE 1 Main techniques used for body composition analysis

Techniques	Advantages	Disadvantages
Magnetic resonance imaging (MRI)	<ul style="list-style-type: none"> – No radiation exposure – Superior spatial resolution and differentiation of body mass composition 	<ul style="list-style-type: none"> – More expensive than BIA and DXA – Longer image acquisition time – Contraindications to MRI may preclude some patients
Dual-energy X-ray absorptiometry (DXA)	<ul style="list-style-type: none"> – Low radiation exposure – More sensitive than BIA – Inexpensive 	<ul style="list-style-type: none"> – Two-dimensional data – Inability to distinguish between subcutaneous and visceral adipose tissue – Low accuracy as compared with CT and MRI – Lack of portability
Computed tomography (CT)	<ul style="list-style-type: none"> – High accuracy and reproducible findings – Ability to define lean body mass, subcutaneous fat, and visceral fat 	<ul style="list-style-type: none"> – More expensive than BIA and DXA – Radiation exposure
Bioelectrical impedance analysis (BIA)	<ul style="list-style-type: none"> – Shorter execution time and immediate results – Portable – Inexpensive – No exposure to radiation 	<ul style="list-style-type: none"> – Lack of precision

Biochemical investigations contribute to the nutritional assessment of IBD patients. The evaluation of deficiencies is crucial, as they can impact the disease activity, quality of life, and even a risk of carcinogenesis.³⁵

Micronutrient deficiency includes all vitamins, especially B₁₂, folate, and vitamin D. Micronutrient deficiency involves low levels of trace elements, such as iron, zinc, and selenium.

Vitamin D is a key micronutrient and prohormone for homeostasis of the skeletal muscles and intestinal system. It is synthesized primarily in the skin and is available in 2 biologically inactive forms, cholecalciferol (vitamin D₃) and ergocalciferol (vitamin D₂). Vitamin D obtained from sun exposure, food, or supplementation is biologically inert and must undergo 2 steps of hydroxylation to become active as 1,25-dihydroxyvitamin D₃ (calcitriol). Active vitamin D, acting via an autocrine mechanism, is essential for proliferation and differentiation of skeletal muscle stem cells, as well as preservation of muscle function.³⁶ Moreover, vitamin D acts through an endocrine mechanism that involves increasing intestinal calcium absorption and osteoclastic activity, and thus is essential for bone growth, density, and remodeling.³⁷ A Polish study³⁸ clarifies how vitamin D may not be the only factor influencing bone mineral density in IBD patients, and suggests how these patients should supplement a higher dose of vitamin D than healthy adults.

Vitamin D deficiency is a common abnormality in IBD patients, due to various reasons, such as a lack of sun exposure caused by immunosuppressive treatments, dietary restrictions, and altered absorption.³⁹ Studies have shown that vitamin D plays an important role in maintaining the gut epithelial integrity, innate immune barrier function, development and function of T cells,⁴⁰ and gut microbiota eubiosis.⁴¹ Vitamin D deficiency can worsen IBD symptoms, increase

the risk of mucosal damage, and contribute to sarcopenia,⁴² resulting in increased disease activity, worse quality-of-life scores, and future clinical relapse.⁴³

Iron is critical for forming essential enzymes, red blood cells, and reversible oxygen binding. Iron deficiency is another common clinical problem in IBD and, as in healthy people, it has a very high estimated prevalence, between 36% and 90%.¹⁶ The incidence of iron deficiency anemia in IBD patients is high and often associated with fatigue, with a prevalence of up to 76% of patients.⁴⁴ The causes include inadequate iron intake, malnutrition, chronic blood loss, or inflammation affecting iron absorption. Chronic inflammation is the biggest contributor to this disorder, which often recurs in IBD patients. Proinflammatory cytokines such as IL-6, IL-1, and TNF- α increase hepcidin levels, reduce iron bioavailability,⁴⁵ and lead to chronic anemia.

Causes of nonsideropenic anemia in IBD include deficiencies of vitamin B₁₂ and folic acid. Folate and folic acid, synthetic analogues of vitamin B₉, are necessary for a variety of metabolic activities, including RNA and DNA formation, DNA repair, and DNA methylation, all of which are crucial for maintaining health of the body cells and genome. Patients with CD and UC have significantly decreased folate levels, and it is reported that 28.8% of CD patients and 8.8% of UC patients are folate-deficient.⁴⁶ There are many different causes of folate deficiency in IBD, including malabsorption, low intake, and drug-induced (eg, methotrexate) deficiency.⁴⁷

Vitamin B₁₂ is essential for metabolism of macronutrients, DNA synthesis, and nerve function. Its deficiency can lead to macrocytic anemia via impaired folate metabolism, neurologic damage, and hyperhomocysteinemia. Only some receptors found in the terminal ileum can absorb vitamin B₁₂ after its binding with an intrinsic factor

produced in the stomach. This is the reason why this deficiency is common in CD, particularly in patients with resection of more than 20 cm of the distal ileum.⁴⁸

Furthermore, poor oral intake and intrinsically malabsorptive nature of IBD may contribute to trace element insufficiency in IBD patients, especially of zinc, magnesium, and selenium.⁴⁹

It is important to note that zinc is a crucial micronutrient that supports various bodily functions, such as cellular metabolism, enzyme activity, immune function, and intestinal barrier function.⁵⁰ A study has shown that patients with IBD may have decreased serum zinc concentrations, even when in clinical remission and without overt malabsorption.⁵¹ This highlights the importance of systematic laboratory testing for anemia or micronutrient deficiency in IBD patients, even if they are in remission.⁵¹

Dietary intervention in the management of irritable bowel syndrome in inflammatory bowel disease: a role of popular diets

In the world of IBD, a diet holds a lot of appeal for both patients and health care professionals. It offers patients an opportunity to take control of their disease and improve their quality of life. In fact, a survey of Dutch adults with IBD found that 59% of patients believed that nutrition was at least as important, if not more important, as medication in treating their disease. Additionally, 62% of patients reported success in controlling IBD symptoms through dietary modifications.⁵²

Diet also appears to play a supportive function in biologic therapies, helping to reduce the inflammatory burden, as found for particular exclusion diets, including the anti-inflammatory diet⁵³ and a specific carbohydrate diet.⁵⁴ However, evidence is lacking to support the concept that any dietary model can replace conventional treatments in adult IBD patients. Nevertheless, CD exclusion diet has been described as a possible therapeutic alternative in the case of inability to receive medical therapy or a failure of biologic therapy.⁵⁵ However, recent guidelines for the management of CD and UC in adults do not recommend specific oral diets due to a lack of long-term benefits.⁵⁶

Despite this, popular diets for IBD treatment have been on the rise. They typically include certain foods/nutrients and exclude other, or even entire food groups, claiming therapeutic benefits for general health or for the treatment of specific conditions. However, the evidence to support these claims is often only partial.⁵⁷ In clinical practice, it is well known that a diet plays a key role in symptom management in IBD patients and in preventing the risk of malnutrition and sarcopenia, due to the mechanisms described above.

IBD patients experience a range of gastrointestinal symptoms that often resemble those of IBS, a chronic condition with a very high prevalence in the general population (20%), characterized by abdominal pain or discomfort associated

with a change in stool form or frequency.⁵⁸ According to a recent meta-analysis, nearly 40% of IBD patients suffer from IBS-like symptoms, with even those in remission being more likely to experience them than healthy controls.⁵⁹ As a result, patients often report symptoms without objective evidence of the disease activity, leaving both patient and physician in a quandary. Treating presumed insidious disease would involve potent immunomodulating agents with potential adverse effects and significant financial expense. In this context, the dietary-nutritional approach plays a crucial role in achieving effective symptom relief in this subgroup of patients and managing possible risks associated with malnutrition.

In this narrative review, we collected all original articles that described several popular diets used in IBD, particularly in terms of their effects on bowel symptoms, IBS-like symptoms, and potential risks of malnutrition.

The literature search was performed using the following electronic databases: PubMed, Scopus, and Embase for articles written in English. The last search was performed on August 31, 2023. The terms “gluten free diet,” OR “Mediterranean diet,” OR “plant based diet,” OR “low FODMAP diet,” OR “popular diets” were matched with the phrases “inflammatory bowel diseases” AND “irritable bowel syndrome.” The terms “gluten free diet,” OR “Mediterranean diet,” OR “plant based diet,” OR “low FODMAP diet,” OR “popular diets” were also matched with the phrases “malnutrition” AND “inflammatory bowel diseases.” All terms were searched both as key words and Medical Subject Headings. We hand-searched the bibliography lists of relevant articles (based on titles and abstracts) to provide additional references.

Low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet

The low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet (LFD) is a dietary approach that limits the intake of certain fermentable carbohydrates.⁵³ These include mono-, di-, and oligosaccharides and polyols. Foods high in FODMAPs include dairy products containing lactose, excess fructose, fructans/galactans found in wheat, onion, chickpea, and lentil, and polyols found in peaches and artificial sweeteners. Patients who follow this nutritional approach should start with a strict adherence to LFD for 4–6 weeks, followed by reintroduction of FODMAPs while monitoring their symptoms.⁶⁰

Research has shown that LFD is particularly effective in managing IBS. FODMAP-rich foods pass through the intestine without being broken down and contribute to increased water absorption in the small intestine, while in the large intestine, they are fermented by intestinal bacteria and produce excess gas that leads to pain, discomfort, and bloating.⁶¹ Studies have shown that limiting these easily fermentable and poorly absorbed carbohydrates can help alleviate symptoms

TABLE 2 Main studies investigating the effects of low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet on gastrointestinal symptoms in inflammatory bowel disease

Study	Disease	Design	Comparison	Size	Patients	Length	Outcomes
Cox et al ⁶⁵ (2020)	IBD	Single-blind randomized controlled trial	LFD vs control diet	52 (25 control, 27 LFD)	Adults	4 weeks	LFD can improve persistent gut symptoms with no effects on inflammation.
Prince et al ⁶³ (2016)	IBD	Retrospective analysis	N/A	88 (39 CD, 38 UC, 11 IBD-U)	Adults	6 weeks	LFD can improve IBS symptoms.
Gearry et al ⁶⁴ (2009)	IBD	Retrospective case-control study	N/A	72 (52 CD, 20 UC)	Adults	N/A	LFD adherence improves IBS symptoms.
Halmos et al ⁶⁸ (2016)	CD	Randomized controlled crossover trial	LFD vs typical Australian diet	9	Adults	9 weeks	Higher intake of FODMAPs significantly increased gastrointestinal symptoms without changing the disease activity.
Pedersen et al ⁶² (2017)	CD	Randomized controlled crossover trial	LFD vs control diet	89 (26 CD, 61 UC)	Adults	6 weeks	LFD reduced IBS symptoms and improved quality of life.
Maagaard et al ⁶⁶ (2016)	IBD and IBS	Retrospective cross-sectional study	LFD	180 (131 IBS, 49 IBD)	Adults	16 months	LFD is an efficacious treatment solution in the management of IBS in IBD patients.
Peng et al ⁶⁷ (2022)	IBD	Systematic review and meta-analysis	LFD vs controls	446 (351 LFD, 95 controls)	Adults	N/A	LFD provides benefits for functional gastrointestinal symptoms but does not improve stool consistency and mucosal inflammation in IBD.

Abbreviations: CD, Crohn disease; FODMAPs, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease, unclassified; IBS, irritable bowel syndrome; LFD, low-FODMAP diet; N/A, not available; UC, ulcerative colitis

in patients with IBS, although the data on LFD's efficacy remain somewhat conflicting. Numerous studies have investigated the effectiveness of LFD in IBD patients, and significant decrease in IBS-like symptoms and overall symptom severity scores has been observed in comparison with a normal diet.⁶²⁻⁶⁶ Many of these studies have been included in a recent updated review and meta-analysis⁶⁷ and are summarized in [TABLE 2](#).

Research results indicate that LFD can help improve IBS symptoms in the patients suffering from IBD, without any significant differences in the subgroups categorized by the disease type.⁶⁸ However, the study did not yield any significant differences regarding LFD effectiveness in improving stool consistency and inflammation level in patients with IBD. It is worth mentioning that most of the participants included in the study remained in clinical remission. However, some evidence suggests that undertaking LFD may alter the gut microbiota, but the long-term effects of these changes remain unknown.⁶⁸

Studies on the effect of LFD on micronutrients are limited and yield conflicting results. A 4-week randomized controlled trial (RCT) found lower calcium intake in patients with IBS than in controls following a usual diet,⁶⁹ but another RCT did not find a significant difference in calcium intake.⁷⁰ A study that used a food frequency questionnaire⁷¹ concluded that the intake of various micronutrients was adequate 6 to 18 months after implementing the LFD. However, another small study⁷² showed that fiber intake was below baseline at 3 months. Moreover, a recent systematic review⁷³ suggests that LFD may

contribute to vitamin D deficiency. On the positive side, an RCT showed that after implementing LFD, there were no significant differences in the intake of energy or macronutrients in comparison with control diets, and there were indications that LFD might improve overall dietary intake. For example, intake of vitamin B₁₂ was higher than in the habitual control diet, which could represent a greater intake of eggs or fish.⁷⁰

Gluten-free diet A gluten-free diet (GFD) is a dietary plan that excludes foods containing gluten, a protein found in wheat, barley, rye, and triticale. It is conventionally used for individuals with celiac disease. Hidden sources of gluten may also include thickening or flavoring agents used to enhance the taste of food. Foods allowed in the gluten-free diet include gluten-free grains, such as rice and corn, fresh meat or poultry, fresh fruits and vegetables, and dairy products. This diet has been further extended to individuals with nonceliac gluten sensitivity (NCGS), a disorder characterized by an improvement in gastrointestinal symptoms similar to IBS with the elimination of gluten, despite a lack of a genetic and immunologic phenotype typical of celiac disease.⁷⁴

The role of diet in celiac disease is well understood, but its utility in IBD is less clear. A recent systematic review and meta-analysis⁷⁵ highlighted a lack of prospective controlled studies on the effects of GFD on inflammation in IBD patients. Although many IBD patients report following a GFD, assuming its beneficial effects on the disease symptoms, the current evidence on whether the GFD can improve gastrointestinal functional

TABLE 3 Main studies investigating the effects of gluten-free diet on gastrointestinal symptoms in inflammatory bowel disease

Study	Disease	Design	Comparison	Size	Patients	Length	Outcomes
Herfarth et al ⁷⁶ (2014)	IBD	Cross-sectional survey study	N/A	1647	Adults	N/A	20% of patients reported following a GFD, more than half of the patients reported improved intestinal symptoms.
Schreiner et al ⁷⁷ (2019)	IBD	Prospective internet-based cohort study	GFD vs non-GFD	1254	Adults	9 years	4.7% of the study population followed a GFD and did not find any differences in the disease activity, complications, and hospitalization rate; worse psychological wellbeing in those who followed the GFD.
Limketkai et al ⁷⁸ (2018)	IBD	Cross-sectional survey study	NCGS IBD vs non-NCGS IBD	102 (55 CD, 46 UC, 3 IBD-U)	Adults	N/A	No difference in gastrointestinal symptoms between patients with and without GS. GS was associated with a recent flare, stenotic disease in CD, and dermatologic manifestations.
Morton et al ⁷⁹ (2020)	IBD	Retrospective observational study	GFD vs non-GFD	233	Adults	12 months	66% of the patients reported improvement of the symptoms and 38% reported reduced flare frequency and severity.

Abbreviations: GFD, gluten-free diet; GS, gluten sensitivity; NCGS, nonceliac gluten sensitivity; others, see [TABLE 2](#)

symptoms or influence IBD severity overall is contradictory ([TABLE 3](#)).

A survey conducted in a Western IBD population⁷⁶ revealed that 20% of 1647 enrolled patients reported following the GFD. More than half of these patients reported improvement in intestinal and extraintestinal symptoms, and 40% claimed reduction in IBD flares while on the GFD.

Another study⁷⁷ revealed that 4.7% of 1223 participants followed the GFD with no significant differences in the disease activity, hospitalization, or surgery rate between the patients following and not following the GFD. In a cross-sectional study,⁷⁸ no differences in symptom frequency were found between IBD patients with and without NCGS. Despite a high percentage of patients with NCGS IBD who were on the GFD, more participants reported recent flares or dermatologic complications. Morton et al,⁷⁹ who investigated 233 IBD patients, found that 66% showed symptom improvement and 38% a reduction in the frequency and severity of relapses after following the GFD.

There have been only a few studies evaluating the nutritional value of GFD, but they were conducted several decades ago and have limited relevance now. Since then, new gluten-free and grain alternatives have become available for patients following this diet. Recent studies conducted in several countries focusing on celiac patients have presented conflicting evidence regarding completeness of the GFD with respect to macronutrient and micronutrient intake.

A recent study⁸⁰ found that celiac patients consumed more energy in the form of fat and less in the form of carbohydrates. Mariani et al⁸¹ attributed this to the fact that carbohydrate-based foods, such as bread and pasta, were replaced by natural and processed foods rich in protein and fat. Analysis of the diet of adult celiac patients revealed that only 46% of women consumed the recommended amount of dietary fiber due to reduced

consumption of grain products.⁸² However, recently developed gluten-free products made from alternative grains and pseudograins, such as quinoa, have an optimal fiber content and could improve the situation.⁸⁰ Another study⁸² found that the GFD did not meet the recommended intake of thiamine, riboflavin, niacin, folic acid, and iron. This evidence is partly explained by low iron and micronutrient enrichment of starch- or cereal-based gluten-free products.

Plant-based diet It is widely known that a Western diet, which is rich in refined carbohydrates, saturated fatty acids, and ultraprocessed foods, is one of the major environmental factors contributing to the increasing incidence and prevalence of IBD due to its proinflammatory effects.⁸³ Plant-based diets (PBDs) aim to maximize consumption of plant-based food, such as vegetables and fruits, and increase fiber intake while minimizing consumption of animal and processed products. Depending on the level of animal product restriction, PBD can be vegan, lacto-ovovegetarian, semivegetarian, or pescatarian.⁸⁴ It has been demonstrated that high amounts of dietary fiber decrease the risk of developing CD,⁸⁵ mainly by increasing the production of SCFAs by gut microbiota. These substances, such as acetate, butyrate, and propionate, have anti-inflammatory and immunomodulatory properties that improve integrity of the intestinal barrier.

Current clinical studies show that PBD may have a role rather in preventing disease flares than managing IBS ([TABLE 4](#)).

In a clinical study⁸⁶ including 691 IBD patients, Western diets were compared with PBDs, and the researchers found out that the latter were linked to a decreased risk of active symptoms. Furthermore, in a prospective clinical trial on CD patients in remission,⁸⁷ the effectiveness of a semivegetarian diet in preventing CD relapse was investigated, with a remission rate

TABLE 4 Main studies investigating the effects of plant-based diets on gastrointestinal symptoms and prevention of disease relapse in inflammatory bowel disease

Study	Disease	Design	Comparison	Size	Patients	Length	Outcomes
Limketkai et al ⁸⁶ (2022)	IBD	Retrospective study	PBD vs Western diet	691 (36% CD and 64% UC or IBD-U)	Adults	Usual diet, recalled from the last 3 months or when in clinical remission	Diets with increased intake of fruits and vegetables, reduction of processed meats and refined carbohydrates, and preference of water for hydration were associated with lower risk of active IBD symptoms.
Chiba et al ⁸⁷ (2010)	CD	Prospective, single-center, clinical trial	SVD vs non-SVD (omnivorous diet group)	22	Adults	24 months	SVD was highly effective in preventing CD relapse.
Hanai et al ⁸⁹ (2004) ^a	UC	Prospective, randomized clinical trial	GBF + conventional treatment vs conventional treatment alone	59	Adults in remission	12 months	GBF appeared to be effective and safe as a maintenance therapy to taper steroid dose and prolong remission in patients with UC.
Hallert et al ⁸⁸ (1991) ^a	UC	Randomized controlled trial	Ispaghula husk vs placebo	29	Adults in remission	4 months	Ispaghula can be helpful in the management of gastrointestinal symptoms in quiescent UC.

a Studies investigating the effect of specific components enhanced in each diet

Abbreviations: GBF, germinated barley foodstuff; SVD, semivegetarian diet; others, see [TABLE 2](#)

TABLE 5 Main studies investigating the effects of the Mediterranean diet on gastrointestinal symptoms in inflammatory bowel disease

Study	Disease	Design	Comparison	Size	Patients	Length	Outcomes
Godny et al ⁹⁹ (2020)	UC	Prospective observational study	N/A	153	Adults	3–8 years	MD decreases intestinal inflammation and potentially reduces symptoms.
Chicco et al ⁹⁸ (2020)	IBD	Prospective clinical trial	N/A	142 (58 CD, 84 UC)	Adults	6 months	MD improves the disease activity and reduces malnutrition-related parameters.
Morvaridi et al ⁹⁷ (2020) ^a	UC	Randomized crossover clinical trial	Extra virgin olive oil vs canola oil	40	Adults	3 weeks	Intake of extra virgin olive oil decreased inflammatory markers and improved gastrointestinal symptoms in UC patients.

a Studies investigating the effect of specific components enhanced in each diet

Abbreviations: MD, Mediterranean diet; others, see [TABLE 2](#)

around 100% after 1 year and 92% after 2 years. Moreover, several controlled studies revealed benefits of adding fiber to the diet of patients with UC.^{88,89}

Despite biologic support for PBDs, additional high-quality evidence is required to fully comprehend their function in the management of IBS in IBD.

In terms of the risk of malnutrition, studies have shown that a PBD can effectively maintain adequate levels of micronutrients and macronutrients. A cross-sectional Epic Oxford Study⁹⁰ that included healthy patients evaluated nutritional adequacy of a PBD. At the end of the observational period, all micronutrient values were found to be in line with reference guidelines, except for vitamin D and calcium, which were deficient in both plant-based and omnivorous diets. The PBDs are well balanced and rich in whole grains, legumes, nuts, and seeds, thus providing an adequate intake of protein. It should be noted that patients were receiving vitamin B₁₂ supplements, therefore in clinical practice this value needs to be kept under control given its presence

in animal products. With the added benefit of a decrease in trans and saturated fats, refined carbohydrates, and a significant increase in fiber intake, no additional shortfall was shown.⁹¹

Mediterranean diet Mediterranean diet (MD) represents a dietary pattern based on large amounts of monounsaturated fatty acids, omega-3 polyunsaturated fatty acids, dietary fiber, and phytochemicals which combine to provide its favorable anti-inflammatory and antioxidant effects.⁹² Its main components include legumes, vegetables, fruits, nuts, and seeds, with a low intake of processed food, red meat, and processed meat. A traditional MD includes a regular intake of olive oil, which has been associated with health-promoting effects.⁹³

MD also plays a role in preventing IBD, including a modulation of the gut microbiota.⁹⁴ Several in vitro studies demonstrated anti-inflammatory effects of olive oil^{95,96} and its ability to reduce the production of proinflammatory mediators (IL-1 β , IL-6, IL-8, and TNF- α), improving intestinal integrity.

This evidence had prompted researchers to test MD, or dietary components that are particularly prominent in it, in patients with active disease in order to evaluate its effects on gut inflammation. However, we have no data regarding efficacy of this diet on managing IBS-like symptoms in IBD patients in remission (TABLE 5).

In a randomized crossover clinical trial,⁹⁷ consumption of 50 ml of extra virgin olive oil for 20 days reduced gastrointestinal symptoms such as bloating, constipation, fecal urgency, and incomplete defecation, and reduced the level of inflammatory markers in UC patients. In a prospective interventional study,⁹⁸ all IBD patients with moderate to severe illness achieved remission or had mild disease activity after 6 months on the MD. The improvement in the disease activity was further confirmed by a significantly higher number of patients in whom fecal calprotectin normalized after the dietary intervention. A recent prospective study involving patients with UC also reported that strict adherence to the MD is associated with a significant reduction in fecal calprotectin levels after pouch surgery.⁹⁹

This dietary pattern is an excellent representation of beneficial nutritional quality; in addition to better dietary fat quality, anti-inflammatory effects, and higher consumption of antioxidants, we must also include increased nutritional adequacy, with an added advantage of a nonrestrictive diet. Higher adherence to MD has been correlated with an increased prevalence of individuals showing adequate micronutrient intake.¹⁰⁰

Conclusions It is currently recognized that diet can play an additional role in the management of gastroenterologic and nutritional issues in patients with IBD. This is the first review that concentrates on the effects of popular diets on the symptoms of IBS in these patients.

The LFD was found effective in controlling IBS symptoms in IBD patients when maintained for a short period of time. However, there are concerns about its long-term sustainability and potential nutritional risks. On the other hand, there are no prospective studies on the GFD, MD, and PBD, but GFD may be a viable option for patients with NCGS, a condition that can often co-occur with IBS. Meanwhile, MD and PBD are thought to be beneficial in reducing inflammation and general intestinal symptoms.

However, the data collected from these studies are often marred by study design, risk of bias, confounding factors, lack of control or randomization as well as significant heterogeneity in definitions of efficacy. This, for example, may be caused by a difficulty physicians and researchers often encounter in distinguishing occult disease activity from true IBS. Therefore, the best dietary approach in this setting remains an individualized one, with the goal of improving the patient's symptoms and quality of life, while preventing the onset of malnutrition or correcting nutritional gaps and dietary imbalances.

ARTICLE INFORMATION

ACKNOWLEDGMENTS None.

FUNDING None.

CONFLICT OF INTEREST None declared.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

HOW TO CITE Covello C, Becherucci G, Scaldaferri F, et al. Popular diets and nutritional assessment in the management of irritable bowel syndrome in inflammatory bowel disease: an overview of current evidence. *Pol Arch Intern Med.* 2024; 134: 16659. doi:10.20452/pamw.16659

REFERENCES

- Dixon LJ, Kabi A, Nickerson KP, McDonald C. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. *Inflamm Bowel Dis.* 2015; 21: 912-922. [↗](#)
- Mentella MC, Scaldaferri F, Pizzoferrato M, et al. Nutrition, IBD and gut microbiota: a review. *Nutrients.* 2020; 12: 944. [↗](#)
- Zagórowicz E, Walkiewicz D, Kucha P, et al. Nationwide data on epidemiology of inflammatory bowel disease in Poland between 2009 and 2020. *Pol Arch Intern Med.* 2022; 132: 16194. [↗](#)
- Gassull MA, Cabré E. Nutrition in inflammatory bowel disease. *Curr Opin Clin Nutr Metab Care.* 2001; 4: 561-569. [↗](#)
- Takaoka A, Sasaki M, Nakanishi N, et al. Nutritional screening and clinical outcome in hospitalized patients with Crohn's disease. *Ann Nutr Metab.* 2017; 71: 266-272. [↗](#)
- Elia M. Defining, recognizing, and reporting malnutrition. *Int J Low Extrem Wounds.* 2017; 16: 230-237. [↗](#)
- Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia. *Clin Geriatr Med.* 2017; 33: 17-26. [↗](#)
- Balestrieri P, Ribolsi M, Guarino MPL, et al. Nutritional aspects in inflammatory bowel diseases. *Nutrients.* 2020; 12: 372. [↗](#)
- Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol.* 2012; 107: 1474-1482. [↗](#)
- Sharma K, Mogensen KM, Robinson MK. Pathophysiology of critical illness and role of nutrition. *Nutr Clin Pract.* 2019; 34: 12-22. [↗](#)
- Vrdoljak J, Vilović M, Živković PM, et al. Mediterranean diet adherence and dietary attitudes in patients with inflammatory bowel disease. *Nutrients.* 2020; 12: 3429. [↗](#)
- Casanova MJ, Chaparro M, Molina B, et al. Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease. *J Crohns Colitis.* 2017; 11: 1430-1439.
- Zallot C, Quilliot D, Chevaux JB, et al. Dietary beliefs and behavior among inflammatory bowel disease patients. *Inflamm Bowel Dis.* 2013; 19: 66-72. [↗](#)
- Späte U, Schulze PC. Proinflammatory cytokines and skeletal muscle. *Curr Opin Clin Nutr Metab Care.* 2004; 7: 265-269. [↗](#)
- Liu C, Zhu S, Zhang J, et al. Inflammatory bowel diseases, interleukin-6 and interleukin-6 receptor subunit alpha in causal association with cerebral cortical structure: a Mendelian randomization analysis. *Front Immunol.* 2023; 14: 1154746. [↗](#)
- Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD: malnutrition and/or sarcopenia? A practical guide. *Gastroenterol Res Pract.* 2017; 2017: 8646495. [↗](#)
- Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. *Nutrition.* 2008; 24: 694-702. [↗](#)
- Battat R, Scherl EJ, Lukin D, et al. Increased primary bile acids with ileocolonic resection impact ileal inflammation and gut microbiota in inflammatory bowel disease. *J Crohns Colitis.* 2023; 17: 795-803. [↗](#)
- Wu EH, Guo Z, Zhu WM. Postoperative diarrhea in Crohn's disease: pathogenesis, diagnosis, and therapy. *World J Clin Cases.* 2023; 11: 7-16. [↗](#)
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing.* 2019; 48: 16-31. [↗](#)
- Gold SL, Raman M, Sands BE, et al. Review article: putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2023; 57: 1216-1230. [↗](#)
- Ryan E, McNicholas D, Creavin B, et al. Sarcopenia and inflammatory bowel disease: a systematic review. *Inflamm Bowel Dis.* 2019; 25: 67-73. [↗](#)
- Zhang T, Ding C, Xie T, et al. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. *Clin Nutr.* 2017; 36: 1586-1592. [↗](#)

- 24 Parada Venegas D, de la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front Immunol*. 2019; 10: 277. [↗](#)
- 25 Ehlers L, Bannert K, Rohde S, et al. Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. *J Cell Mol Med*. 2020; 24: 8304-8314. [↗](#)
- 26 Nardone OM, de Sire R, Petito V, et al. Inflammatory bowel diseases and sarcopenia: the role of inflammation and gut microbiota in the development of muscle failure. *Front Immunol*. 2021; 12: 694217. [↗](#)
- 27 Singh A, Wall C, Levine A, et al. Nutritional screening and assessment in inflammatory bowel disease. *Indian J Gastroenterol*. 2022; 41: 5-22. [↗](#)
- 28 Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr*. 2003; 22: 321-336. [↗](#)
- 29 Jansen I, Prager M, Valentini L, Büning C. Inflammation-driven malnutrition: a new screening tool predicts outcome in Crohn's disease. *Br J Nutr*. 2016; 116: 1061-1067. [↗](#)
- 30 Norman K, Stobäus N, Gonzalez MC, et al. Hand grip strength: outcome predictor and marker of nutritional status. *Clin Nutr*. 2011; 30: 135-142. [↗](#)
- 31 Weir CB, Jan A. BMI classification percentile and cut off points. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024-. <https://www.ncbi.nlm.nih.gov/books/NBK541070/>. Accessed June 26, 2023.
- 32 Ackermans LLGC, Rabou J, Basrai M, et al. Screening, diagnosis and monitoring of sarcopenia: when to use which tool? *Clin Nutr ESPEN*. 2022; 48: 36-44. [↗](#)
- 33 Emerenziani S, Biancone L, Guarino MPL, et al. Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNF α therapy. *Dig Liver Dis*. 2017; 49: 495-499. [↗](#)
- 34 Chaves LGCM, Gonçalves TJM, Bitencourt AGV, et al. Assessment of body composition by whole-body densitometry: what radiologists should know. *Radiol Bras*. 2022; 55: 305-311. [↗](#)
- 35 Hosomi K, Kunisawa J. The specific roles of vitamins in the regulation of immunosurveillance and maintenance of immunologic homeostasis in the gut. *Immune Netw*. 2017; 17: 13-19. [↗](#)
- 36 Remelli F, Vitali A, Zurlo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. *Nutrients*. 2019; 11: 2861. [↗](#)
- 37 de la Puente Yagüe M, Collado Yurrita L, Ciudad Cabañas MJ, Cuadrado Cenxual MA. Role of vitamin D in athletes and their performance: current concepts and new trends. *Nutrients*. 2020; 12: 579. [↗](#)
- 38 Ratajczak AE, Szymczak-Tomczak A, Michalak M, et al. Associations between vitamin D, bone mineral density, and the course of inflammatory bowel disease in Polish patients. *Pol Arch Intern Med*. 2022; 132: 16329. [↗](#)
- 39 Taylor L, Almutairdi A, Shommu N, et al. Cross-sectional analysis of overall dietary intake and Mediterranean dietary pattern in patients with Crohn's disease. *Nutrients*. 2018; 10: 1761. [↗](#)
- 40 Raman M, Milestone AN, Walters JR, et al. Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. *Therap Adv Gastroenterol*. 2011; 4: 49-62. [↗](#)
- 41 Charoenngam N, Shirvani A, Kalajian TA, et al. The effect of various doses of oral vitamin D₃ supplementation on gut microbiota in healthy adults: a randomized, double-blinded, dose-response study. *Anticancer Res*. 2020; 40: 551-556. [↗](#)
- 42 Yin K, Agrawal DK. Vitamin D and inflammatory diseases. *J Inflamm Res*. 2014; 7: 69-87. [↗](#)
- 43 Gubatan J, Chou ND, Nielsen OH, Moss AC. Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2019; 50: 1146-1158. [↗](#)
- 44 Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. *Nat Rev Gastroenterol Hepatol*. 2010; 7: 599-610. [↗](#)
- 45 Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. *Int J Chronic Dis*. 2018; 2018: 9394060. [↗](#)
- 46 Yakut M, Ustün Y, Kabaçam G, Soykan I. Serum vitamin B₁₂ and folate status in patients with inflammatory bowel diseases. *Eur J Intern Med*. 2010; 21: 320-323. [↗](#)
- 47 Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. *J Rheumatol*. 2004; 31: 2374-2381.
- 48 Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. *Inflamm Bowel Dis*. 2008; 14: 217-223. [↗](#)
- 49 Weissshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. *Curr Opin Clin Nutr Metab Care*. 2015; 18: 576-581. [↗](#)
- 50 Halsted JA, Ronaghy HA, Abadi P, et al. Zinc deficiency in man. The Shiraz experiment. *Am J Med*. 1972; 53: 277-284. [↗](#)
- 51 Piątek-Guziewicz A, Paśko P, Wcisło K, et al. Serum levels of selected micronutrients in patients with inflammatory bowel disease in clinical remission. *Pol Arch Intern Med*. 2021; 131: 701-708. [↗](#)
- 52 de Vries JHM, Dijkhuizen M, Tap P, Witteman BJM. Patient's dietary beliefs and behaviours in inflammatory bowel disease. *Dig Dis*. 2019; 37: 131-139. [↗](#)
- 53 Olendzki B, Bucci V, Cawley C, et al. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: pilot study. *Gut Microbes*. 2022; 14: 2046244. [↗](#)
- 54 Yan J, Wang L, Gu Y, et al. Dietary patterns and gut microbiota changes in inflammatory bowel disease: current insights and future challenges. *Nutrients*. 2022; 14: 4003. [↗](#)
- 55 Sigall Boneh R, Sarbagili Shabat C, Yanai H, et al. Dietary therapy with the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy. *J Crohns Colitis*. 2017; 11: 1205-1212. [↗](#)
- 56 Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: clinical nutrition in inflammatory bowel disease. *Clin Nutr*. 2017; 36: 321-347. [↗](#)
- 57 Weber AT, Shah ND, Sauk J, Limketkai BN. Popular diet trends for inflammatory bowel diseases: claims and evidence. *Curr Treat Options Gastroenterol*. 2019; 17: 564-576. [↗](#)
- 58 Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. *Gastroenterology*. 2006; 130: 1480-1491. [↗](#)
- 59 Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2012; 107: 1474-1482. [↗](#)
- 60 Barrett JS. How to institute the low-FODMAP diet. *J Gastroenterol Hepatol*. 2017; 32: 8-10. [↗](#)
- 61 Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut*. 2015; 64: 93-100. [↗](#)
- 62 Pedersen N, Ankersen DV, Felding M, et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. *World J Gastroenterol*. 2017; 23: 3356-3366. [↗](#)
- 63 Prince AC, Myers CE, Joyce T, et al. Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2016; 22: 1129-1136. [↗](#)
- 64 Geary RB, Irving PM, Barrett JS, et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. *J Crohns Colitis*. 2009; 3: 8-14. [↗](#)
- 65 Cox SR, Lindsay JO, Fromentin S, et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. *Gastroenterology*. 2020; 158: 176-188. [↗](#)
- 66 Maagaard L, Ankersen DV, Végh Z, et al. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. *World J Gastroenterol*. 2016; 22: 4009-4019. [↗](#)
- 67 Peng Z, Yi J, Liu X. A Low-FODMAP diet provides benefits for functional gastrointestinal symptoms but not for improving stool consistency and mucosal inflammation in IBD: a systematic review and meta-analysis. *Nutrients*. 2022; 14: 2072. [↗](#)
- 68 Halmos EP, Christophersen CT, Bird AR, et al. Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets. *Clin Transl Gastroenterol*. 2016; 7: 164. [↗](#)
- 69 Staudacher HM, Kurien M, Whelan K. Nutritional implications of dietary interventions for managing gastrointestinal disorders. *Curr Opin Gastroenterol*. 2018; 34: 105-111. [↗](#)
- 70 Staudacher HM, Ralph FSE, Irving PM, et al. Nutrient intake, diet quality, and diet diversity in irritable bowel syndrome and the impact of the low FODMAP diet. *J Acad Nutr Diet*. 2020; 120: 535-547. [↗](#)
- 71 O'Keefe M, Jansen C, Martin L, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. *Neurogastroenterol Motil*. 2018; 30: e13154. [↗](#)
- 72 Harvie RM, Chisholm AW, Bisanz JE, et al. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. *World J Gastroenterol*. 2017; 23: 4632-4643. [↗](#)
- 73 Comeche JM, Gutierrez-Hervás A, Tuells J, et al. Predefined diets in patients with inflammatory bowel disease: systematic review and meta-analysis. *Nutrients*. 2020; 13: 52. [↗](#)
- 74 Aljada B, Zohni A, El-Matary W. The gluten-free diet for celiac disease and beyond. *Nutrients*. 2021; 13: 3993. [↗](#)
- 75 Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, et al. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. *Cochrane Database Syst Rev*. 2019; 2: CD012839. [↗](#)
- 76 Herfarth HH, Martin CF, Sandler RS, et al. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. *Inflamm Bowel Dis*. 2014; 20: 1194-1197. [↗](#)
- 77 Schreiner P, Yilmaz B, Rossel JB, et al. Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. *United European Gastroenterol J*. 2019; 7: 767-781. [↗](#)

- 78 Limketkai BN, Sepulveda R, Hing T, et al. Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease. *Scand J Gastroenterol*. 2018; 53: 147-151. [↗](#)
- 79 Morton H, Pedley KC, Stewart RJC, Coad J. Inflammatory bowel disease: are symptoms and diet linked? *Nutrients*. 2020; 12: 2975. [↗](#)
- 80 Martin J, Geisel T, Maresch C, et al. Inadequate nutrient intake in patients with celiac disease: results from a German dietary survey. *Digestion*. 2013; 87: 240-246. [↗](#)
- 81 Mariani P, Viti MG, Montuori M, et al. The gluten-free diet: a nutritional risk factor for adolescents with celiac disease? *J Pediatr Gastroenterol Nutr*. 1998; 27: 519-523. [↗](#)
- 82 Thompson T, Dennis M, Higgins LA, et al. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? *J Hum Nutr Diet*. 2005; 18: 163-169. [↗](#)
- 83 Rizzello F, Spisni E, Giovanardi E, et al. Implications of the Westernized diet in the onset and progression of IBD. *Nutrients*. 2019; 11: 1033. [↗](#)
- 84 Tuso PJ, Ismail MH, Ha BP, Bartolotto C. Nutritional update for physicians: plant-based diets. *Perm J*. 2013; 17: 61-66. [↗](#)
- 85 Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. *Gastroenterology*. 2013; 145: 970-977. [↗](#)
- 86 Limketkai BN, Hamideh M, Shah R, et al. Dietary patterns and their association with symptoms activity in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2022; 28: 1627-1636. [↗](#)
- 87 Chiba M, Abe T, Tsuda H, et al. Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. *World J Gastroenterol*. 2010; 16: 2484-2495. [↗](#)
- 88 Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. *Scand J Gastroenterol*. 1991; 26: 747-750. [↗](#)
- 89 Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. *Int J Mol Med*. 2004; 13: 643-647. [↗](#)
- 90 Davey GK, Spencer EA, Appleby PN, et al. EPIC-Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK. *Public Health Nutr*. 2003; 6: 259-269. [↗](#)
- 91 Jakše B, Jakše B, Pinter S, et al. Nutrient and food intake of participants in a whole-food plant-based lifestyle program. *J Am Coll Nutr*. 2021; 40: 333-348. [↗](#)
- 92 Martinez-Gonzalez MA, Martin-Calvo N. Mediterranean diet and life expectancy; beyond olive oil, fruits, and vegetables. *Curr Opin Clin Nutr Metab Care*. 2016; 19: 401-407. [↗](#)
- 93 López-Miranda J, Pérez-Jiménez F, Ros E, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. *Nutr Metab Cardiovasc Dis*. 2010; 20: 284-294.
- 94 Khalili H, Håkansson N, Chan SS, et al. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies. *Gut*. 2020; 69: 1637-1644. [↗](#)
- 95 Cardeno A, Sanchez-Hidalgo M, Aparicio-Soto M, Alarcón-de-la-Lastra C. Unsaponifiable fraction from extra virgin olive oil inhibits the inflammatory response in LPS-activated murine macrophages. *Food Chem*. 2014; 147: 117-123. [↗](#)
- 96 Cárdeno A, Magnusson MK, Strid H, et al. The unsaponifiable fraction of extra virgin olive oil promotes apoptosis and attenuates activation and homing properties of T cells from patients with inflammatory bowel disease. *Food Chem*. 2014; 161: 353-360. [↗](#)
- 97 Morvaridi M, Jafarirad S, Seyedian SS, et al. The effects of extra virgin olive oil and canola oil on inflammatory markers and gastrointestinal symptoms in patients with ulcerative colitis. *Eur J Clin Nutr*. 2020; 74: 891-899. [↗](#)
- 98 Chicco F, Magni S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. *Inflamm Bowel Dis*. 2021; 27: 1-9. [↗](#)
- 99 Godny L, Reshef L, Pfeffer-Gik T, et al. Adherence to the Mediterranean diet is associated with decreased fecal calprotectin in patients with ulcerative colitis after pouch surgery. *Eur J Nutr*. 2020; 59: 3183-3190. [↗](#)
- 100 Castro-Quezada I, Román-Viñas B, Serra-Majem L. The Mediterranean diet and nutritional adequacy: a review. *Nutrients*. 2014; 6: 231-248. [↗](#)